These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37732232)

  • 21. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of incident atrial fibrillation in heart failure with preserved or reduced ejection fraction: A community-based study.
    Zhang P; Chamberlain AM; Hodge DO; Cai C; Xiao PL; Han J; Jiang CY; Redfield MM; Roger VL; Cha YM
    J Cardiovasc Electrophysiol; 2020 Sep; 31(9):2275-2283. PubMed ID: 32584498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Optimization of Guideline-Directed Medical Therapy during Hospitalization among Patients with Heart Failure with Reduced Ejection Fraction in Daily Clinical Practice.
    Bánfi-Bacsárdi F; Muk B; Pilecky D; Duray GZ; Kiss RG; Nyolczas N
    Cardiology; 2023; 148(1):27-37. PubMed ID: 36470212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term impact of angiotensin receptor-neprilysin inhibitor based on short-term treatment response in heart failure.
    Park HK; Park JS; Kim MS; Lee E; Choi H; Park YJ; Park BE; Kim HN; Kim N; Bae MH; Lee JH; Park HS; Cho Y; Jang SY; Yang DH
    ESC Heart Fail; 2023 Dec; 10(6):3430-3437. PubMed ID: 37705397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.
    Stolfo D; Lund LH; Benson L; Lindberg F; Ferrannini G; Dahlström U; Sinagra G; Rosano GMC; Savarese G
    Eur J Heart Fail; 2023 Sep; 25(9):1648-1658. PubMed ID: 37419495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing angiotensin receptor-neprilysin inhibitors with sodium-glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus.
    Tsai ML; Lin Y; Lin MS; Tsai TH; Yang NI; Wang CY; Hsieh IC; Hung MJ; Chen TH
    Diabetol Metab Syndr; 2023 May; 15(1):110. PubMed ID: 37237322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
    Tromp J; Ouwerkerk W; van Veldhuisen DJ; Hillege HL; Richards AM; van der Meer P; Anand IS; Lam CSP; Voors AA
    JACC Heart Fail; 2022 Feb; 10(2):73-84. PubMed ID: 34895860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atrial resynchronization therapy in patients with atrial fibrillation and heart failure with and without systolic left ventricular dysfunction: a pilot study.
    Saksena S; Slee A; Saad M
    J Interv Card Electrophysiol; 2018 Oct; 53(1):9-17. PubMed ID: 29987682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
    Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Significance of New-Onset Atrial Fibrillation in Heart Failure with Preserved, Mid-Range, and Reduced Ejection Fraction Following Acute Myocardial Infarction: Data from the NOAFCAMI-SH Registry.
    Hao C; Luo J; Liu B; Xu W; Li Z; Gong M; Qin X; Shi B; Wei Y
    Clin Interv Aging; 2022; 17():479-493. PubMed ID: 35444413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction.
    Son MK; Park JJ; Lim NK; Kim WH; Choi DJ
    Heart; 2020 Aug; 106(15):1160-1168. PubMed ID: 32341140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes.
    Inciardi RM; Giugliano RP; Park JG; Nordio F; Ruff CT; Chen C; Lanz HJ; Antman EM; Braunwald E; Solomon SD
    JACC Clin Electrophysiol; 2023 Apr; 9(4):569-580. PubMed ID: 37100536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction.
    Black-Maier E; Ren X; Steinberg BA; Green CL; Barnett AS; Rosa NS; Al-Khatib SM; Atwater BD; Daubert JP; Frazier-Mills C; Grant AO; Hegland DD; Jackson KP; Jackson LR; Koontz JI; Lewis RK; Sun AY; Thomas KL; Bahnson TD; Piccini JP
    Heart Rhythm; 2018 May; 15(5):651-657. PubMed ID: 29222043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.
    Zafrir B; Lund LH; Laroche C; Ruschitzka F; Crespo-Leiro MG; Coats AJS; Anker SD; Filippatos G; Seferovic PM; Maggioni AP; De Mora Martin M; Polonski L; Silva-Cardoso J; Amir O;
    Eur Heart J; 2018 Dec; 39(48):4277-4284. PubMed ID: 30325423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ARNI in HFrEF-One-Centre Experience in the Era before the 2021 ESC HF Recommendations.
    Niemiec R; Morawska I; Stec M; Kuczmik W; Swinarew AS; Stanula A; Mizia-Stec K
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction.
    Clemmer JS; Ward TJ; Lirette ST
    ESC Heart Fail; 2023 Jun; 10(3):2010-2018. PubMed ID: 37042079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart Failure Therapies following Acute Coronary Syndromes with Reduced Ejection Fraction: Data from the ACSIS Survey.
    Zafrir B; Ovdat T; Abu Akel M; Bahouth F; Orvin K; Beigel R; Amir O; Elbaz-Greener G
    J Pers Med; 2023 Jun; 13(6):. PubMed ID: 37374004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction.
    Packer M
    J Card Fail; 2019 Dec; 25(12):986-1003. PubMed ID: 31541742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.